European Psychiatry - Volume 33 - March 2016

133 / 812

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S116–S348 S129
Aims To compare depressive, manic, and matched controls
regarding their sexuality.
Methods The current study is an observational cross sectional
study, carried out on 173 women, among them 112 bipolar, diag-
nosed according to ICD-10 criteria (81 depressive, and 31 manic),
and 61 controls. All subjects fulfilled the Sexual Disorders Interview
(SDI), Female Sexual Function Index (FSFI) and to bipolar patients
BDI, YMRS have been administered.
Results Female bipolar patients were significant less sexual
active than controls, depressivewomenbeing less interested in sex-
uality than manic patients; there were not significant differences
between the two patients’ samples regarding the frequency of sex-
ual intercourse, degree of psychopathology. Sexual problems on
FSFI were detected in 75% of bipolar patients, both bipolar groups
emphasizing difficulties in arousal, lubrication and sexual satisfac-
tion.
Conclusions The issue of sexual problems in bipolar female
patients is delicate to investigate and often neglected, being dif-
ficult to ascertain to the mood disorder itself or to different
treatments the patients have been exposed to, or to stigma.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW38
A peripheral composite proteomic
and gene expression biomarker
related to diagnosis and affective state
in rapid cycling bipolar disorder
K. Munkholm ∗, M. Vinberg , L.V. Kessing
Psychiatric Center Copenhagen, Rigshospitalet, Copenhagen,
Denmark
∗ Corresponding author.
Introduction Management of bipolar disorder is limited by
absence of laboratory test. While alterations related to multiple
biological pathways have been found in bipolar disorder, findings
have not translated into clinically applicable biomarkers. We pre-
viously found promise for a combined gene expression biomarker.
The combination of gene expression and proteomic biomarkers
could have potential as a meaningful clinical test.
Objectives To identify a composite biomarker based on mul-
tiple potential peripheral biomarkers related to neuroplasticity,
inflammation and oxidative stress, both on a proteomic and gene
expression level.
Aims To test the ability of a composite biomarker to discriminate
between bipolar disorder patients and healthy control subjects and
between affective states in bipolar disorder patients.
Methods mRNA expression of a set of 19 candidate genes and
protein levels of immune markers and neurotrophic factors were
measured in peripheral blood mononuclear cells and combined
with urinary levels of oxidized nucleosides of 37 rapid cycling bipo-
lar disorder patients in different affective states (depression, mania
and euthymia) during a 6–12-month period and in 40 age- and
gender-matched healthy control subjects. A composite measure
was constructed in the first half of the sample and independently
validated in the second half of the sample. The composite measure
was evaluated using ROC curves and by calculating sensitivity and
specificity.
Results Statistical analysis is ongoing. Results will be presented
at the congress.
Conclusions Aperipheral composite biomarker based onmultiple
biological pathways on both proteomic and gene expression levels
may have potential as a clinically applicable biomarker.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW39
Ketamine effect of the neural
response of emotinal processing
H. Nießen
Leibniz Institute for Neurobiology, Clinical Affective Neuroimaging
Laboratory, Magdeburg, Germany
Introduction The NMDA antagonist ketamine has shown a good
antidepressant effect in drug resistant patients with MDD. The
exact mechanism of these antidepressant effects are unknown but
some studies indicate that ketamine changes neuronal emotion
processing. Amygdala is an important brain structure for the emo-
tion processing in people with affective disorders. Previous studies
showed functional and morphological changes, for example ele-
vated neuronal activation in the amygdala in depressive patient.
Previous studies also indicated that ketamine seems to inhibit this
elevated amygdala function.
Methods Sixty-three healthy subjects (28 female, group mean
age 25.65± 4.32 years) took part in a double-blinded fMRI study.
Half of the participants received ketamine infusion with 0,5mg/kg
BW, and half received placebo (saline infusion). To investigate the
temporal development of the drug impact, the experiment was
repeated at three time points: baseline, one hour and 24 hours after
the infusion. We used a block design with positive and negative
facial expressions and forms (task adapted from Hariri [7]). Pre-
processing and statistical data analysis were performed in SPM8.
Results We found a continuous suppression of the amygdala
during negative face recognition in the ketamine group, with a
maximum 24 hours after infusion.
Conclusion Ketamine seems to inhibit amygdala function during
negative face perception.
Disclosure of interest The author has not supplied his/her decla-
ration of competing interest.
EW40
Assessment of executive functions in
bipolar depression
R. Paunescu ∗ iclutia
Iuliu Hatieganu University of Medicine and Pharmacy,
Neurosciences, Cluj-Napoca, Romania
∗ Corresponding author.
Introduction Cognitive functions in bipolar disorder have been
assessed during acute mood episodes but also during remission.
While other cognitive functions, such as verbal and working mem-
ory, attention, verbal fluency and psychomotor speed seem to
recover after the acute episode, executive functions impairment
remains also during remission; this aspect led to the assumption
that executive functions may be a trait marker for bipolar disorder.
Objective The purpose of this study was to assess the executive
functions, such as cognitive flexibility, set shifting, problem solving
and abstract thinking in bipolar depression compared to healthy
subjects.
Method Forty patients diagnosed with Bipolar Disorder and
Major Depressive Episode according to DSM IV-TR were included
into the study. Executive functions were investigated using Wis-
consin Card Sorting Test (WCST). Results obtained by patients were
compared with those of 30 healthy who underwent the same cog-
nitive evaluation.
Results Depressed bipolar patients scored significantly worse on
the majority of WCST measures. Thus, for total trials, total errors,
preservative errors andpreservative responses (rawscores andper-
cents) and failure to maintain set scores, the differences between
the two groups were significant at the 1% threshold ( P = 0.000). The
patients and controls displayed similar behavior for total correct
(P = 0.215) and conceptual levels scores (P = 0.421).